Jacobs Levy Equity Management
CMPI

Jacobs Levy Equity Management’s Checkmate Pharmaceuticals, Inc. Common Stock CMPI Stock Holding History

Jacobs Levy Equity Management’s Portfolio CMPI Stock Details CMPI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-36,511
Closed -$145K – 1129
2021
Q3 		$145K Buy
+36,511
New +$188K ﹤0.01% 1005

Other funds holding CMPI

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Jacobs Levy Equity Management's CMPI Position: Q4 2021 in Review

Jacobs Levy Equity Management sold out of Checkmate Pharmaceuticals, Inc. Common Stock (CMPI) in Q4 2021, closing a stake of 36,511 shares — an estimated $145K sold.

Jacobs Levy Equity Management first reported a position in CMPI in Q3 2021 and held it in 1 quarter. The position peaked at $145K in Q3 2021. 25 funds tracked by Wall St. Rank hold CMPI as of Q4 2021.

  • Jacobs Levy Equity Management reported no remaining Checkmate Pharmaceuticals, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 36,511 Checkmate Pharmaceuticals, Inc. Common Stock shares in Q4 2021, an estimated $145K.
  • Jacobs Levy Equity Management first reported a position in Checkmate Pharmaceuticals, Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • Jacobs Levy Equity Management's Checkmate Pharmaceuticals, Inc. Common Stock position peaked at $145K in Q3 2021.
  • 25 funds tracked by Wall St. Rank held Checkmate Pharmaceuticals, Inc. Common Stock as of Q4 2021.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2021, filed 14 Feb 2022.